CR11249A - Formulaciones de anticuerpos - Google Patents

Formulaciones de anticuerpos

Info

Publication number
CR11249A
CR11249A CR11249A CR11249A CR11249A CR 11249 A CR11249 A CR 11249A CR 11249 A CR11249 A CR 11249A CR 11249 A CR11249 A CR 11249A CR 11249 A CR11249 A CR 11249A
Authority
CR
Costa Rica
Prior art keywords
formulations
antibodies
stable
nacl
citrate
Prior art date
Application number
CR11249A
Other languages
English (en)
Inventor
E Brisbane Charlene
Sharad Ketkar Amol
Tove Lashmar Ulla
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40228991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11249(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CR11249A publication Critical patent/CR11249A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)

Abstract

Esta invencion se refiere a formulaciones de anticuerpo estables a la temperatura y la cizalladura que son mas estables comparadas con una formulacion estandar (tal como citrato 30 mM, NaCl 100 mM, pH 6,5).
CR11249A 2007-07-06 2010-02-02 Formulaciones de anticuerpos CR11249A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94822007P 2007-07-06 2007-07-06

Publications (1)

Publication Number Publication Date
CR11249A true CR11249A (es) 2010-03-08

Family

ID=40228991

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11249A CR11249A (es) 2007-07-06 2010-02-02 Formulaciones de anticuerpos

Country Status (38)

Country Link
US (2) US20110020328A1 (es)
EP (2) EP2170388B1 (es)
JP (1) JP5529017B2 (es)
KR (2) KR101670454B1 (es)
CN (1) CN101820912B (es)
AR (2) AR067455A1 (es)
AU (1) AU2008275278B2 (es)
BR (2) BRPI0814003B1 (es)
CA (1) CA2692681C (es)
CL (1) CL2008001984A1 (es)
CO (1) CO6270340A2 (es)
CR (1) CR11249A (es)
CY (3) CY1118419T1 (es)
DK (2) DK2889310T3 (es)
DO (1) DOP2010000001A (es)
EA (1) EA017994B1 (es)
ES (2) ES2610821T3 (es)
FR (1) FR21C1040I1 (es)
HR (2) HRP20170033T1 (es)
HU (3) HUE038501T2 (es)
IL (1) IL202950A (es)
JO (1) JO3219B1 (es)
LT (3) LT2170388T (es)
MA (1) MA31471B1 (es)
MX (1) MX2010000017A (es)
MY (1) MY210424A (es)
NO (2) NO2889310T3 (es)
NZ (1) NZ582250A (es)
PE (1) PE20090738A1 (es)
PL (2) PL2170388T3 (es)
PT (2) PT2170388T (es)
SI (2) SI2170388T1 (es)
TR (1) TR201802928T4 (es)
TW (2) TWI515204B (es)
UA (1) UA107557C2 (es)
UY (1) UY31210A1 (es)
WO (1) WO2009009407A1 (es)
ZA (1) ZA200909107B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
WO2009009406A1 (en) * 2007-07-06 2009-01-15 Smithkline Beecham Corporation Antibody formulations
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
RU2012139181A (ru) 2010-02-26 2014-04-10 Ново Нордиск А/С Стабильная композиция, содержащая антитело
KR20190047135A (ko) 2010-03-01 2019-05-07 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
MX2012013586A (es) 2010-05-28 2013-01-24 Novo Nordisk As Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante.
CA2832560A1 (en) * 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations with reduced viscosity
TWI907924B (zh) * 2011-05-02 2025-12-11 日商武田藥品工業股份有限公司 抗-α4β7抗體之調配物
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CN111973484A (zh) * 2013-03-12 2020-11-24 普莱玛疗法公司 包含螯合剂和碱的牙用组合物
EP2805730A1 (en) * 2013-05-21 2014-11-26 Bergen Teknologioverforing AS Nitric oxide donor for the treatment of chronic fatigue syndrome
WO2015162504A1 (en) 2014-04-23 2015-10-29 Novartis Ag Novel dosing and uses of ofatumumab
WO2016189491A1 (en) * 2015-05-28 2016-12-01 Glaxosmithkline Intellectual Property Development Limited Novel formulation
CN109563161A (zh) * 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
PT3497132T (pt) 2016-08-15 2020-09-25 Novartis Ag Regimes e métodos de tratamento de esclerose múltipla que usam ofatumumab
WO2018179138A1 (ja) * 2017-03-29 2018-10-04 持田製薬株式会社 抗体含有液体製剤
CN110352201A (zh) 2017-04-03 2019-10-18 免疫医疗公司 用于癌症疗法的抗体药物缀合物的皮下施用
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3618871A4 (en) 2017-05-02 2021-01-06 Merck Sharp & Dohme Corp. FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
CA3033195A1 (en) * 2018-02-09 2019-08-09 Ecolab Usa Inc. Flowability testing systems and methods
JP7467438B2 (ja) 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｒｓｖ抗体の製剤及びその使用方法
WO2020092233A1 (en) 2018-10-31 2020-05-07 Merck Sharp & Dohme Corp. Anti-human pd-1 antibody crystals and methods of use thereof
MX2021005394A (es) 2018-11-07 2021-07-06 Merck Sharp & Dohme Llc Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
CN121445862A (zh) 2019-09-11 2026-02-03 诺华股份有限公司 奥法木单抗治疗患者中除多发性硬化症以外病症的管理
MX2022003010A (es) 2019-09-11 2022-06-02 Novartis Ag Tratamiento de la emr mediante cambio de terapia.
CN112675126A (zh) * 2019-10-18 2021-04-20 百奥泰生物制药股份有限公司 抗cd20抗体制剂及其应用
EP4132564A1 (en) 2020-04-09 2023-02-15 Novartis AG Ofatumumab for treating ms while maintaining serum igg
IL297986A (en) 2020-05-08 2023-01-01 Genmab As Bispecific antibodies against cd3 and cd20
JP7057954B2 (ja) * 2020-09-03 2022-04-21 国立大学法人大阪大学 改善された保存安定性を有するタンパク質含有液体製剤
WO2022219057A1 (en) 2021-04-14 2022-10-20 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients
EP4387999A1 (en) 2021-08-16 2024-06-26 Novartis AG Ofatumumab for treating pediatric ms
JP2025513510A (ja) * 2022-04-20 2025-04-24 アルトス バイオロジックス インク． オクレリズマブを含む薬学的組成物とその用途
CN116712390B (zh) * 2023-08-04 2023-11-14 上海览屹医药科技有限公司 一种高浓度高稳定性的抗体制剂及其制备方法
WO2025037335A1 (en) * 2023-08-12 2025-02-20 Dr. Reddy's Laboratories Limited Formulations of anti-cd20 antibody

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4816401A (en) * 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
CA2292730C (en) * 1997-06-13 2008-09-16 Genentech, Inc. Stabilized antibody formulation
HUP0203133A3 (en) * 1999-10-04 2005-07-28 Chiron Corp Emeryville Stabilized liquid polypeptide-containing pharmaceutical compositions
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2003068821A2 (en) 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
SI1946776T1 (sl) * 2002-02-27 2017-07-31 Immunex Corporation Stabiliziran tnfr-fc sestavek, ki obsega arginin
JP2005530845A (ja) * 2002-06-21 2005-10-13 アイデック ファーマシューティカルズ コーポレイション 抗体を濃縮するための緩衝化処方物およびその使用方法
KR101348472B1 (ko) * 2002-10-17 2014-01-07 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
EP1590364B1 (en) * 2002-12-16 2011-10-05 Genmab A/S Human monoclonal antibodies against interleukin 8 (il-8)
US8084582B2 (en) * 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
ES2707284T3 (es) * 2005-03-08 2019-04-03 Pfizer Prod Inc Composiciones de anticuerpo anti-CTLA-4
CA2623429C (en) * 2005-09-30 2015-01-13 Medimmune Limited Interleukin-13 antibody composition
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
WO2009009406A1 (en) * 2007-07-06 2009-01-15 Smithkline Beecham Corporation Antibody formulations

Also Published As

Publication number Publication date
ZA200909107B (en) 2012-12-27
IL202950A0 (en) 2011-08-01
CY2021027I1 (el) 2021-12-31
EP2170388B1 (en) 2016-10-12
AU2008275278A1 (en) 2009-01-15
CY1120047T1 (el) 2018-12-12
PE20090738A1 (es) 2009-07-18
NO2889310T3 (es) 2018-05-19
NO2021036I1 (no) 2021-09-13
TWI515204B (zh) 2016-01-01
TR201802928T4 (tr) 2018-03-21
KR20100038092A (ko) 2010-04-12
CO6270340A2 (es) 2011-04-20
CN101820912A (zh) 2010-09-01
PT2889310T (pt) 2018-03-26
TWI612060B (zh) 2018-01-21
SI2889310T1 (en) 2018-04-30
ES2663504T3 (es) 2018-04-13
JP5529017B2 (ja) 2014-06-25
PL2170388T3 (pl) 2017-06-30
LT2889310T (lt) 2018-03-26
LT2170388T (lt) 2017-01-10
HRP20170033T1 (hr) 2017-03-24
IL202950A (en) 2014-05-28
DK2889310T3 (en) 2018-03-26
HUS2100038I1 (hu) 2021-10-28
NZ582250A (en) 2012-04-27
TW201623334A (zh) 2016-07-01
PT2170388T (pt) 2017-01-04
FR21C1040I1 (fr) 2021-11-19
CN101820912B (zh) 2014-03-12
BRPI0814003B1 (pt) 2021-06-15
KR101670454B1 (ko) 2016-10-31
EA201070105A1 (ru) 2010-08-30
JP2011526880A (ja) 2011-10-20
KR20150088335A (ko) 2015-07-31
CY1118419T1 (el) 2017-06-28
HRP20180440T1 (hr) 2018-04-20
EA017994B1 (ru) 2013-04-30
DOP2010000001A (es) 2010-01-31
JO3219B1 (ar) 2018-03-08
AR067455A1 (es) 2009-10-14
TW200914466A (en) 2009-04-01
EP2170388A4 (en) 2011-07-06
HK1207652A1 (en) 2016-02-19
UA107557C2 (xx) 2015-01-26
HK1141979A1 (zh) 2010-11-26
BR122020026978B1 (pt) 2021-09-28
HUE038501T2 (hu) 2018-10-29
MX2010000017A (es) 2010-04-07
EP2170388A1 (en) 2010-04-07
CL2008001984A1 (es) 2009-01-09
SI2170388T1 (sl) 2017-01-31
UY31210A1 (es) 2009-01-30
EP2889310B1 (en) 2017-12-20
MY210424A (en) 2025-09-22
BRPI0814003A2 (pt) 2015-02-03
US20150158951A1 (en) 2015-06-11
EP2889310A1 (en) 2015-07-01
PL2889310T3 (pl) 2018-06-29
MA31471B1 (fr) 2010-06-01
AR109461A2 (es) 2018-12-12
ES2610821T3 (es) 2017-05-03
CA2692681A1 (en) 2009-01-15
AU2008275278B2 (en) 2011-04-14
WO2009009407A1 (en) 2009-01-15
LTPA2021520I1 (es) 2021-10-11
HUE031288T2 (hu) 2017-06-28
CA2692681C (en) 2018-12-04
US20110020328A1 (en) 2011-01-27
CY2021027I2 (el) 2021-12-31
DK2170388T3 (en) 2017-01-16

Similar Documents

Publication Publication Date Title
CR11249A (es) Formulaciones de anticuerpos
CR10444A (es) Anticuerpo humanizado de c-kit
CR10528A (es) Proceso para producir poxvirus y composiciones de poxvirus
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
CY1114769T1 (el) Διασπαρσιμα στο νερο αγροχημικα σκευασματα που αποτελουνται απο πολυαλκοξυτριγλυκεριδια ως υποκινητες διεισδυσης
HN2008001191A (es) Compuestos de biciclolactama sustituida
MX353706B (es) Anticuerpos contra csf-1r humano y usos de los mismos.
HN2008000188A (es) 7- aza- indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y su utilizacion
CR9746A (es) Bazedoxifene acetate formulations
MX387734B (es) Combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
EP1863921A4 (en) EXPRESSION OF SOLUBLE, ACTIVE, EUKARYOTIC GLUCOSE TRANSFERASES IN PROKARYOTIC ORGANISMS
CO6571886A2 (es) Antagonistas de pcsk9
CR9821A (es) Metodos y composiciones para el control genetico de infestaciones de insectos en plantas
MX2007013759A (es) Agentes de union de esclerostina.
CR20110409A (es) Metodos para reducir la proliferacion y viabilidad de los agentes microbianos
PA8650801A1 (es) Composiciones y formulaciones de ecteinascidina, como la ecteinascidina 743
PA8671301A1 (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricación y utilización
CL2012000508A1 (es) Composicion para la aplicacion en cultivos agricolas al aire libre o invernaderos que comprende zeolita, y aditivos; uso de la composicion para aumentar el rendimiento de los cultivos agricolas.
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
UY30534A1 (es) Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapéutica como antagonistas de los receptores de urotensina ii
PA8625201A1 (es) Composiciones de peróxido estabilizadas
GT200500357A (es) Indazoles substituidos, composicones que los comprenden, procedimiento de su preparacion y utilizacion
UY31128A1 (es) Formulacion de nevirapina de liberacion prolongada
AR075299A1 (es) Formulacion con tendencias de formacion reducida de geles y metodo para reducir la tendencia de formacion de geles